Story thread · 2 reports / 2 sources
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
endpts.com · 9h · first report
Ying Huang has spent the past seven years building up one of the leading cancer cell therapy players. Now, just weeks after announcing his departure as Legend Biotech's CEO, Huang is stepping ...
The coverage
- Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
biopharmadive.com · 4h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.